Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 276

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Prognostic Significance of Copy-Number Alterations in Multiple Myeloma

Open access
Avet-Loiseau, Hervé, Li, Cheng, Magrangeas, Florence, Gouraud, Wilfried, Charbonnel, Catherine, Harousseau, Jean-Luc, Attal, Michel, Marit, Gerald, Mathiot, Claire, Facon, Thierry, Moreau, Philippe, Anderson, Kenneth C., Campion, Loïc, Munshi, Nikhil C., Minvielle, Stéphane · 2009 · Journal of Clinical Oncology

Abstract

Purpose: Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown. Patients and Methods: We performed a genome-wide analysis of malignant plasma cells from 192 newly diagnosed patients with myeloma using high-density, single-nucleotide polymorphism (SNP) arrays to identify genetic lesions associated with prognosis. Results: Our analyses revealed deletions and amplifications in 98% of patients. Amplifications in 1q and deletions in 1p, 12p, 14q, 16q, and 22q were the most frequent lesions associated with adverse prognosis, whereas recurrent amplifications of chromosomes 5, 9, 11, 15, and 19 conferred a favorable prognosis. Multivariate analysis retained three independent lesions: amp(1q23.3), amp(5q31.3), and del(12p13.31). When adjusted to the established prognostic variables (ie, t(4;14), del(17p), and serum β 2-microglobulin [Sβ 2 M]), del(12p13.31) remained the most powerful independent adverse marker (P < .0001; hazard ratio [HR], 3.17) followed by Sβ 2 M (P < .0001; HR, 2.78) and the favorable marker amp(5q31.3) (P = .0005; HR, 0.37). Patients with amp(5q31.3) alone and low Sβ 2 M had an excellent prognosis (5-year overall survival, 87%); conversely, patients with del(12p13.31) alone or amp(5q31.3) and del(12p13.31) and high Sβ 2 M had a very poor outcome (5-year overall survival, 20%). This prognostic model was validated in an independent validation cohort of 273 patients with myeloma. Conclusion: These findings demonstrate the power and accessibility of molecular karyotyping to predict outcome in myeloma. In addition, integration of expression of genes residing in the lesions of interest revealed putative features of the disease driving short survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.20.6136

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 276

Metadata

Authors
Avet-Loiseau, H., Li, C., Magrangeas, F., Gouraud, W., Charbonnel, C., Harousseau, J.-L., Attal, M., Marit, G., Mathiot, C., Facon, T., Moreau, P., Anderson, K. C., Campion, L., Munshi, N. C., & Minvielle, S.
Venue
Journal of Clinical Oncology
Published
2009-09-20
Volume
27
Issue
27
Pages
4585-4590
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163999353
Cited by
276
References
39
FWCI
15.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. https://app.cochat.ai/papers/10.1200/jco.2008.20.6136
The paper
Avet-Loiseau, H., Li, C., Magrangeas, F., Gouraud, W., Charbonnel, C., Harousseau, J.-L., Attal, M., Marit, G., Mathiot, C., Facon, T., Moreau, P., Anderson, K. C., Campion, L., Munshi, N. C., & Minvielle, S. (2009). Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.6136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.